This NICE guideline provides recommendations for non-specialists for the identification and referral guidance for children and adults who present with symptoms or risk factors of acute kidney injury.
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism
Some drugs used for the treatment of myeloma can increase the risk of venous thromboembolic events. This NICE guidelines outlines how healthcare professionals can manage patients who may be at higher risk of developing VTE in hospital.
This paper, written by a panel of experts from the International Myeloma Working Group (IMWG), reviews the available data on second primary malignancies in myeloma, and provides recommendations for treatment and management.
This paper by the International Myeloma Working Group, reviews the available evidence and provides recommendations for the management of myeloma-related kidney disease
These guidelines, produced by an expert panel on behalf of the European Myeloma Network (EMN), provide recommendations for the management of the most common complications of myeloma, including bone and kidney disease.
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
In this guidance NICE outlines recommendations for the use of erythropoiesis-stimulating agents for the treatment of anaemia in cancer patients undergoing chemotherapy.
This paper, written by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the available evidence and provides recommendations for the management of myeloma-related bone disease. It also includes expert consensus to propose additional recommendations where there were insufficient published data.
IMWG Recommendations for the prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
This paper, produced by the International Myeloma Working Group, summarises the available evidence and provides recommendations for a prophylaxis strategy according to a risk assessment model, to reduce the risk of a venous thromboembolic event in myeloma patients.
This paper, written by an expert panel on behalf of the International Myeloma Working Group, outlines the state of knowledge of treatment-induced peripheral neuropathy in myeloma patients and the various management practices, providing recommendations for the optimal management of patients who develop peripheral neuropathy during treatment.
This NICE guidance outlines recommendations for the prevention, identification and management of neutropenic sepsis in people with cancer.